INOVIO dosed first participant in phase 2 trial for its DNA vaccine against MERS, a Coronavirus Disease
On Aug. 4, 2021, Inovio Pharma announced that the company had dosed the first Phase 2 trial subject…
On Aug. 4, 2021, Inovio Pharma announced that the company had dosed the first Phase 2 trial subject…
On Aug. 3, 2021, CytoDyn announced that Brazil’s regulatory authority ANVISA (Agência Nacional de Vigilância Sanitária) has approved…
On Jul. 29, 2021, the National Institutes of Health (NIH) announced it had launched a new online research…
On Jul. 28, 2021, GlaxoSmithKline and Vir Biotechnology announced they had signed a Joint Procurement Agreement with the…
On Jul. 26, 2021, Trevena announced that the first COVID-19 patient had been enrolled in the NIH-funded ACTIV-4…
On Jun. 29, 2021, Rigel Pharma announced that fostamatinib, the Company’s novel oral spleen tyrosine kinase (SYK) inhibitor,…
On Jun. 29, 2021, Altimmune provided an update on its AdCOVID investigational vaccine for the prevention of COVID-19….
On Jun. 8, 2021, Mayo Clinic researchers and colleagues at the University of Minnesota showed that COVID-19 exacerbates…
On May 27, 2021, Innovation Pharma announced that patient enrollment in the Company’s 120-patient, Phase 2 clinical trial…
On May 18, 2021, GlaxoSmithKline and Medicago reported positive interim Phase 2 clinical trial safety and immunogenicity data for…
On May 6, 2021, Trevena announced that TRV027, the Company’s novel AT1 receptor selective agonist, had been selected…
On Apr. 15, 2021, CytoDyn announced it had executed an exclusive supply and distribution agreement with Chiral Pharma…
On Apr. 12, 2021, Resverlogix announced that it had successfully received its desired ‘No Objection Letter’ from Health…
On Nov. 30, 2020, Moderna announced that the primary efficacy analysis of the Phase 3 study of mRNA-1273…
On Nov. 18, 2020, Gilead Sciences announced topline results from the Phase 2/3 CAPELLA trial evaluating the company’s…
On Nov. 13, 2020, NeuroRx and Relief Therapeutics announced that to-date, 150 patients (out of a targeted enrollment…
On Nov. 9, 2020, ImmunityBio announced positive study results for their human Ad5 (hAd5) COVID-19 vaccine candidate, which…
On Nov. 6, 2020, Novartis announced new data from an interim analysis for the randomized, double-blind, placebo-controlled CAN-COVID…
On Nov. 4, 2020, Mateon Therapeutics announced the receipt of approval from Instituto Nacional de Salud (INS), the…
On Oct. 23, 2020, Entos Pharmaceuticals announced it was receiving advisory services and funding of up to $5…
On Oct. 23, 2020, AstraZeneca announced that the clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, had…
On Oct. 19, 2020, Mateon Therapeutics announced the receipt of approval from Republica Argentina Poder Ejecutivo Nacional, the…
On Oct. 19, 2020, LabCorp announced a test that provided a quantitative measurement of an individual’s SARS-CoV-2 IgG…
On Oct. 15, 2020, Ionis Pharmaceuticals announced that IONIS-PKK-LRx was being evaluated in an investigator-initiated Phase 2 clinical…
On Oct. 13, 2020, NeoGenomics announced plans to open a state-of-the-art research laboratory in China in association with…
On Oct. 7, 2020, in a continuing effort to provide the facts about ID NOW to support public…
On Oct. 6, 2020, AIM ImmunoTech announced that it had received Institutional Review Board approval for the expansion…
On Oct. 2, 2020, AstraZeneca announced the phase I/II clinical trial for the COVID-19 vaccine AZD1222 had resumed…
On Sept. 30, 2020, University of Oxford researchers announced they had begun a new study to explore the…
On Sept. 30, 2020, the National Institutes of Health (NIH) announced funding of a nationwide study to discover…